Sponsor content

Late-stage atopic dermatitis treatment on target

With OC459, a first-in-class, oral, once-a-day small molecule for atopic dermatitis, Atopix has a potential winner for this and other type 2 helper T cell–mediated disorders such as severe asthma and related allergic conditions. To download the full article, please sign in.

1
Upvote 1
Page of
Go to the profile of Atopix Therapeutics Ltd

Atopix Therapeutics Ltd

Atopix Therapeutics Limited is a clinical stage biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma.